Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells

14 Nov 2022

Abstract excerpt

BACKGROUND AIMS: The targeting of solid cancers with chimeric antigen receptor (CAR) T cells faces many technological hurdles, including selection of optimal target antigens. Promising pre-clinical and clinical data of CAR T-cell activity have emerged from targeting surface antigens such as GD2 and B7H3 in childhood cancer neuroblastoma. Anaplastic lymphoma kinase (ALK) is expressed in a majority of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Neuroblastoma Research and Treatments
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36396552
DOI: 10.1016/j.jcyt.2022.10.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cellsPMID 36396552Read ↗

From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapySemantic proximity Read ↗

Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen induced exhaustionSemantic proximity Read ↗

GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicitySemantic proximity Read ↗

An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersSemantic proximity Read ↗

Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity Read ↗

State of the Art in Immunotherapy of NeuroblastomaSemantic proximity Read ↗

An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastomaSemantic proximity Read ↗

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity Read ↗

An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastomaSemantic proximity Read ↗

Antigen Specificity and Cell Engineering Determine CAR T Cell Efficacy in Group 3 MedulloblastomaSemantic proximity Read ↗

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacySemantic proximity Read ↗

Exploring and Targeting the Tumor Immune Microenvironment of NeuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.